Core Insights - Teladoc Health has appointed Susan Salka to its board of directors, effective immediately, following the retirements of Eric Evans and Thomas McKinley [1] - Salka brings extensive healthcare leadership and governance experience, having previously served as president and CEO of AMN Healthcare Services, where she contributed to significant revenue growth [2] - Salka's appointment is expected to enhance Teladoc's strategic direction in care delivery transformation and value creation [2][4] Company Overview - Teladoc Health is recognized as the global leader in virtual care, focusing on delivering and orchestrating care across various stakeholders, including patients, providers, and health systems [4] - The company aims to improve access to healthcare, drive better outcomes, extend provider capacity, and reduce costs through its innovative virtual care solutions [4] Board Composition - Susan Salka will serve on the audit and compensation committees of the board, bringing her expertise from her tenure at AMN Healthcare, where she was instrumental in the company's strategic success and made 26 acquisitions [2][3] - Salka holds an MBA in Finance and has served on multiple boards, including Parexel International and McKesson Corporation, indicating her strong governance background [3]

Core Insights - OneMedNet Corporation has announced a strategic partnership with ViuHealth to enhance its Real-World Data (RWD) offerings, particularly in the autoimmune disease sector [1][2] Group 1: Partnership Details - The partnership will integrate ViuHealth's longitudinal autoimmune disease data into OneMedNet's iRWD™ platform, which is powered by Palantir Foundry, thereby increasing the scale and diversity of regulatory-grade RWD [2][6] - ViuHealth will provide ongoing data that captures patient journeys, treatment adherence, flares, and outcomes, which will support pharmaceutical partners in drug discovery and market strategies [3][4] Group 2: Market Opportunity - The autoimmune therapeutics market is projected to exceed $166 billion globally in 2026, indicating a significant opportunity for pharmaceutical and biotechnology companies to leverage the enriched datasets for drug development and regulatory evidence [3][14] - Autoimmune diseases affect approximately 8% of the U.S. population, representing tens of millions of individuals, creating strong demand for longitudinal real-world data in life sciences and digital health [5][14] Group 3: Revenue Growth Strategy - This partnership is expected to drive OneMedNet's subscription revenue growth by integrating high-value, disease-specific data into the iRWD™ platform, making it more attractive for ongoing subscriptions rather than one-time sales [4][14] - The collaboration aims to create predictable Annual Recurring Revenue (ARR) and enhance customer retention through expanded data feeds [14] Group 4: Company Positioning - OneMedNet is positioning itself as a trusted data infrastructure provider in specialty disease areas, reinforcing its role in the rapidly growing real-world data and AI-enabled healthcare markets [7][8] - The company aims to build repeatable, subscription-oriented data partnerships that generate continuous data flows, enhancing its ability to deliver relevant cohorts reflecting real-world patient journeys [7][14]

Core Insights - Teladoc Health, Inc. (NYSE:TDOC) is recognized as one of the best American penny stocks to invest in, with recent price target adjustments from BofA Securities and Goldman Sachs [1][3]. Group 1: Price Target Adjustments - BofA Securities reduced its price target for Teladoc from $7.50 to $7 while maintaining a Neutral rating [1]. - Goldman Sachs also cut its price target from $9 to $8 but retained a Buy rating on the stock [3]. Group 2: User Metrics and Business Segments - BofA noted that BetterHelp's monthly active users in Q4 are 0.2% above Q3 levels but down 18.7% year-over-year, indicating a mixed performance [2]. - Despite the decline in year-over-year metrics, BofA views the quarter-over-quarter flat growth as a positive sign for Teladoc's core Integrated Care business [2]. - There is uncertainty regarding the future growth of both the BetterHelp and Chronic Care segments [2]. Group 3: Company Overview - Teladoc Health is a leading virtual care company providing 24/7 on-demand remote medical care, mental health services, and chronic condition management [4]. - The company facilitates connections between patients and providers for various healthcare needs, including primary care and complex care [4].

Core Insights - Teladoc Health has appointed Michael Smith to its board of directors, bringing over three decades of leadership experience in financial management and strategic transformation [1][2] - Smith's expertise in enterprise transformations is expected to enhance Teladoc's strategic focus for long-term growth as the company continues to scale and innovate [2] - Teladoc Health will release its fourth quarter 2025 results on February 25, 2026, followed by a conference call to discuss the results [3] Company Overview - Teladoc Health is recognized as the global leader in virtual care, facilitating care delivery across various stakeholders including patients, care providers, and health systems [4] - The company aims to improve access to care, drive better health outcomes, extend provider capacity, and reduce costs through its innovative virtual care solutions [4]

Core Viewpoint - Teladoc Health Inc. is set to release its fourth quarter 2025 results on February 25, 2026, after market close, followed by a conference call to discuss the results [1]. Group 1: Conference Call Details - The conference call will be accessible by dialing 1-833-470-1428 for U.S. participants, with an access code of 330912 [2]. - International participants can find global dial-in numbers through a provided link [2]. - A live audio webcast will be available online for the conference call [2]. Group 2: Replay Information - A replay of the conference call will be available via webcast shortly after the call concludes and will remain accessible for approximately 90 days [3]. Group 3: Company Overview - Teladoc Health is recognized as the global leader in virtual care, focusing on transforming virtual care into a catalyst for improved health outcomes [4]. - The company collaborates with health plans, employers, providers, health systems, and consumers to enhance access, drive better outcomes, extend provider capacity, and reduce costs [4].

Transforming how better health happens J.P. Morgan Healthcare Conference January 2026 Safe Harbor This presentation contains, and the officers of Teladoc Health, Inc. (the "Company" or "Teladoc Health") may make, "forward-looking" statements that are based on management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, information concerning possible or assumed future results of operations, including descriptions of ...

Core Insights - Arbiter, a startup founded by Michelle Carnahan, has raised $52 million in seed funding to create a platform that connects healthcare professionals and payers to enhance patient care [1][2] - The funding has been sourced from family offices, leading to a valuation of $400 million for Arbiter [2] - Arbiter aims to utilize AI to streamline interactions among payers, providers, and patients, with over 1,000 clinicians already engaged within six months of its launch [5] Company Background - Michelle Carnahan has extensive experience in healthcare, having worked at Eli Lilly for 26 years and later at Thirty Madison, where she played a key role in achieving a $1 billion valuation [3] - Thirty Madison was acquired by Remedy Meds in a $500 million all-stock deal in September [3] Funding Strategy - Carnahan intentionally chose to raise funds from specialized investors rather than traditional venture capital to expedite the product's market entry [4] - The partnership with family offices and the acquisition of SecondWave Delivery Systems have been pivotal in accelerating Arbiter's market presence [5][6] Mission and Vision - Arbiter's mission is to transform the U.S. healthcare system by aligning payers and providers to create a cohesive system that prioritizes patient needs [7]

Core Insights - Teladoc Health announced the resignation of Chief Financial Officer Mala Murthy, who will leave the company on November 21, 2025, to pursue an opportunity outside the healthcare industry [1][2] - The company reaffirmed its full-year 2025 consolidated revenue and adjusted EBITDA outlook, with preliminary results for Q3 2025 showing consolidated revenue of $626.4 million and adjusted EBITDA of $69.9 million [3][5] Leadership Changes - Mala Murthy will continue in her role until her departure and will present during the company's Q3 earnings conference call [2] - An interim leadership structure will be established during the search for a new CFO, with key finance leaders reporting to CEO Chuck Divita [2][3] Financial Performance - For the three months ended September 30, 2025, Teladoc Health reported a consolidated revenue of $626.4 million and an adjusted EBITDA of $69.9 million [3][18] - The adjusted EBITDA for the same period reflects a decrease from $83.3 million in Q3 2024, indicating a year-over-year decline [18] Upcoming Events - The company will host a conference call on October 29, 2025, to discuss its Q3 2025 financial results, with a news release and presentation materials to be issued prior to the call [4]

Core Insights - Teladoc Health Inc. will release its third quarter 2025 results on October 29, 2025, after market close [1] - A conference call to discuss the results will take place at 5:00 p.m. ET on the same day [1] Conference Call Details - U.S. participants can access the conference call by dialing 1-833-470-1428 with access code 609817 [2] - International participants can find global dial-in numbers through a provided link [2] - A live audio webcast will be available online for those who prefer to listen via the internet [2] Replay Information - A replay of the conference call will be available shortly after its completion and will remain accessible for approximately 90 days [3] Company Overview - Teladoc Health is recognized as the global leader in virtual care, focusing on delivering and orchestrating care across various stakeholders [4] - The company aims to enhance access, improve health outcomes, extend provider capacity, and reduce costs through its extensive relationships with health plans, employers, providers, health systems, and consumers [4]

Group 1 - The company reported a 49% increase in revenue for Q2, reaching $61 million compared to $41.21 million a year earlier, exceeding analysts' expectations of $55.2 million [1][3] - The net loss for the quarter was $5.31 million, translating to a loss of 24 cents per share, an improvement from a net loss of $10.69 million or $1.40 loss per share in the same period last year [1][3] - CEO Sean Duffy highlighted the company's ability to capitalize on trends in cardiometabolic care and advancements in artificial intelligence as key factors in their performance [2]